New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc.

HIND

Healthcare Biotechnology

Vyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.

Revenue
+67.6%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.20 0.25 −17.24%
Market cap
$10.2M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Latest quarter Q3 FY2026 · quarter to September 2026

Revenue growth has picked up two quarters running, from −84.1% to 67.6%.

Q3 FY2026 and the 7 quarters before it
Quarter Revenue, $m Growth, % Op. margin, % EPS, $
Q3 FY26 0 67.6 (1,760.5) (0.13)
Q2 FY26 0 (46.0) (3,194.8) (0.10)
Q1 FY26 0 (84.1) (3,575.6) (0.15)
Q4 FY25 0 (40.4) (3,702.5) (0.21)
Q3 FY25 0 (59.1) (24,781.2) (3.12)
Q2 FY25 0 (97.5) (648.4) (771.90)
Q1 FY25 0 (89.8) (100.2) (761.59)
Q4 FY24 0 (96.9) 5,760.6 —

Growth is on the same quarter a year earlier, and EPS is diluted. Negative figures in brackets.

Capital & Financial Ratios $m

Size
Market Cap 10
Revenue ttm 0
Net income ttm (4)
Free cash flow ttm (4)
Net debt Q (7)
Valuation
P/E n/m
Forward P/E FY26e n/m
Price / sales 55.9 (above 10: high)
Forward P/S FY26e Powerpack
Price / FCF n/m
Price / book 1.3
Financial health
Current ratio Q 3.7 (at or above 1.5: strong)
Debt / equity Q 0.1 (at or below 0.5: strong)
Interest coverage Q (352.1)
Growth
Revenue growth FY26e −61.7% (below 0%: weak)
EPS growth FY26e +87.6% (at or above 15%: strong)
EPS growth FY27e −30.7% (below 0%: weak)
EPS growth, 5 yrs e +45.2% (at or above 15%: strong)
Insiders
Owned by insiders 52.8%

Green and red mark values outside typical ranges; (Q) is the latest quarter; e marks analysts’ estimates, FY26e the fiscal year ending in 2026; n/m is not meaningful, as a P/E on a loss. How we judge →

Compound annual growth

10y 5y 3y
Sales (22.40%) (50.98%) (69.47%)
Cash Flow — — —
Earnings — — —
Book Value — (23.64%) 0.91%

Valuation

P/S against its own 10 years 39.57%
10-year low 10-year high
P/B against its own 10 years 32.32%
10-year low 10-year high
EV/Sales against its own 10 years 19.41%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Analysts’ price targets Wall Street, collected weekly

Analyst price targets

Analysts’ consensus Wall Street average, updated each weekday

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 3 10 9 3 11 14 11 9 0 0 0 (23.1%) 0 0 — (20.9%)
Gross margin, % 17.21 51.29 40.41 10.09 55.42 61.38 60.52 63.93 75.91 68.44 50.39 +51.2 pt
EBT (20) (35) (37) (24) (22) (63) (47) (11) (1) (10) (4) n/m
EBT margin, % (603.21) (350.67) (410.72) (721.61) (193.03) (466.32) (414.54) (130.62) (563.45) (3,277.35) (2,555.61) (2,674.1) pt
Net income (20) (35) (37) (24) (22) (63) (46) (11) (1) (10) (4) n/m
Per share, $
Per share, $ Revenue 0.80 0.59 4.78 0.70 2.89 — 112,400.00 8,678.00 1,065.98 0.15 0.02 (17.1%)
Earnings (4.85) (2.08) (19.63) (5.03) (5.54) (1,453,488.00) — (11,104.65) (6,001.39) (4.86) (0.59) n/m
Cash flow (4.59) (1.83) (15.46) (4.86) (2.19) — (219,020.00) (16,960.00) (2,548.13) (1.73) (0.64) n/m
Capex (0.08) (0.06) (0.67) (0.04) (0.10) — (920.00) (10.00) 1.24 0.00 0.00 n/m
Free cash flow (4.67) (1.89) (16.13) (4.90) (2.29) — (219,940.00) (16,970.00) (2,546.89) (1.73) (0.64) n/m
Book value 15.23 2.10 6.88 3.37 3.71 — 36,610.00 6,663.00 (18,219.92) 1.74 0.93 (21.4%)
Shares, m 4 17 2 5 4 0 0 0 0 2 7 (7.2%)
Valuation, ×
Valuation, × P/E n/m n/m n/m n/m n/m n/m n/m n/m n/m n/m n/m n/m
P/S 99,162,871.79 104,890,153.82 3,767,622.90 2,371,432.79 451,056.17 0.00 0.81 0.18 0.02 63.32 55.90 21,064,320.2
P/B 5,232,246.70 29,615,270.27 2,616,093.39 490,925.04 351,797.04 0.00 2.48 0.23 0.00 5.38 1.31 3,830,634.1
EV/Sales 99,162,852.46 104,890,150.35 3,767,621.38 2,371,428.85 451,057.04 (1.66) 0.47 (0.35) 0.88 48.50 12.73 21,064,315.8
EV/FCF (17,061,843.73) (32,838,000.14) (1,116,400.41) (337,409.28) (570,077.57) 1.43 (0.24) 0.18 (5.83) (4.14) (0.43) (5,192,374.0)
Cash, $m
Cash, $m Operating cash flow (19) (31) (29) (23) (9) (15) (22) (17) (1) (4) (4) n/m
Capex 0 (1) (1) 0 0 0 0 0 0 — — n/m
Free cash flow (20) (32) (31) (23) (9) (16) (22) (17) (1) (4) (4) n/m
Balance, $m
Balance, $m Working capital 73 42 11 14 (3) 22 2 7 (5) 3 6 (30.7%)
Net debt (66) (34) (14) (13) 10 (23) (4) (5) 3 (5) (7) n/m
Shareholders’ equity 64 35 13 16 14 44 4 7 (4) 4 7 (27.1%)
Returns, %
Returns, % ROA (44.02) (52.72) (89.55) (93.25) (75.30) (140.96) (145.16) (104.44) (24.04) (260.50) (48.02) (216.5) pt
ROIC 0.00 (3,384.94) 0.00 (496.88) (32.10) (165.96) 0.00 (456.96) 0.00 0.00 0.00 0.0 pt
ROE (446.59) (69.94) (155.04) (163.53) (142.60) (214.71) (192.58) (220.59) (127.42) 3,262.96 (71.85) +3,709.6 pt
People
People Employees 11 137 103 34 2 47 40 31 18 18 — +5.6%
Revenue/emp, $m 0.31 0.07 0.09 0.10 5.65 0.29 0.28 0.28 0.01 0.02 — (27.2%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026

Vyome Holdings, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AEON AEON Biopharma, Inc. $11.2M — (loss-making) — — n/m −120.53% (below 0%: shrinking) — — Compare
PBM Psyence Biomedical Ltd. $10.9M 0.1× — — n/m −1,628.07% (below 0%: shrinking) — — Compare
RADX Radiopharm Theranostics Limited - Sponsored ADR $10.6M — — — — — — — Compare
HIND Vyome Holdings, Inc. $10.2M — (loss-making) — (loss-making) +67.63% (above 0%: growing) n/m +63.50% (above 0%: growing) 46.21% (1,760.52%)
LSTA Lisata Therapeutics, Inc. $9.8M — (loss-making) — (loss-making) — n/m −279.44% (below 0%: shrinking) 100.00% (3,080.00%) Compare
BIVI BioVie Inc. $9.8M — (loss-making) — — n/m +3.92% (above 0%: growing) 0.00% 0.00% Compare
LEXX Lexaria Bioscience Corp. $9.5M — (loss-making) — (loss-making) — n/m +53.90% (above 0%: growing) 100.00% (7,259.50%) Compare
TCRX TScan Therapeutics, Inc. $9.4M — (loss-making) — (loss-making) −76.66% (below 0%: shrinking) n/m +19.98% (above 0%: growing) 100.00% (5,636.69%) Compare
GDTC CytoMed Therapeutics Limited $9.2M — (loss-making) — (loss-making) — — — 0.00% — Compare
Median of peers $9.8M — — — — −58.31% 100.00% (4,358.34%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed Mar 31, 2026

Ownership

Directors and executive officers, together 33.00%
MNI Ventures 14.26%
Navam Capital Private Limited 10.28%
Krishna Gupta 8.28%
Shiladitya Sengupta 8.17%
Venkat Nelabhotla 8.06%
Iron Pillar Fund I Ltd. 6.48%
Mohanjit Jolly 6.48%
Hunter Ventures Limited 5.83%
Man Kwon Lam 5.58%
Felix Kar Chung Lee 5.58%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Vyome Holdings, Inc. (HIND) Latest News

20 more headlines
All HIND news, as stories →
stockrow.com/HIND · Data as of Nov 18, 2026 · For information only; not investment advice. · © 2026 stockrow.com